HILLSIDE, N.J., April 25, 2007 (PRIME NEWSWIRE) -- InB:Biotechnologies, Inc., a wholly owned subsidiary of Integrated BioPharma, Inc. (Nasdaq:INBP), today announced the membership of its new Scientific Advisory Board. The distinguished Board is supporting the Company's mission to develop and commercialize its innovative technology for plant-made biopharmaceuticals. The Scientific Advisory Board members have been selected for their expertise in the disciplines of vaccinology, immunology, plant molecular biology and clinical product development.
"We are extremely fortunate that these talented individuals have chosen to be a part of our Scientific Advisory Board," commented Geoffrey Schild, Ph.D., CBE, FMedSci, the Chief Scientific Officer of InB:Biotechnologies. "Each member of this Board is contributing appreciable scientific insight and technical experience to maximize the value of our platform technology for production of plant-made vaccines, antibodies and therapeutic proteins."
The nine members of InB:Biotechnologies Scientific Advisory Board are:
Burt D. Ensley, Ph.D., is a noted microbiologist and molecular biologist. He is the Chairman and CEO of DermaPlus Products and is on the faculties of the University of Arizona and Northern Arizona University. Previously, Dr. Ensley was President and Vice President for Research of NuCycle Therapy, Inc. (as InB:Biotechnologies was formerly known), President and CEO of Phytotech, Inc. and headed the Specialty Chemicals Group at Amgen. Dr. Ensley served a six-year term on the National Science Foundation's BIO Directorate Advisory Board.
Reinhard Gluck, Ph.D., is an internationally recognized expert in vaccine development. He has successfully taken a novel adjuvanted delivery platform from concept to market, and has also been instrumental in the development of vaccines against rabies, mumps, measles and rubella. Dr. Gluck is currently Executive Vice President, Research & Development, Vaccine Discovery for Crucell-Berna Biotech in Basel, Switzerland. He is also President of Etna Biotech and President of the Swiss Biotech Association.
William Hartman, Ph.D., is the Vice President of Fraunhofer USA, Inc. He is responsible for the strategic growth and management of the five technology centers operated by the not-for-profit research organization throughout the United States. Dr. Hartman is a former Professor of Mechanics and Materials Science at Johns Hopkins University and has over twenty-five years of executive experience in the development and management of technological businesses.
John Petricciani, M.D., has held senior positions in the public and private sectors in clinical development and regulatory affairs. He is the former Senior Vice President, Medical and Regulatory Affairs at CancerVax Corporation; Vice President, Regulatory Affairs at Genetics Institute, Inc.; and Director of the Office of Biologics at the U.S. Food and Drug Administration. Dr. Petricciani is the Immediate Past President of the International Association for Biologicals (IABS).
Stanley A. Plotkin, M.D., is one of the world's leading experts in vaccinology. He is Professor Emeritus of the University of Pennsylvania and Executive Advisor to Sanofi Pasteur. Over the course of his career, Dr. Plotkin has served as Senior Assistant Surgeon with the Epidemic Intelligence Service of the Centers for Disease Control; Director of the Division of Infectious Diseases and Senior Physician at the Children's Hospital of Philadelphia; Professor of Pediatrics and Microbiology at the University of Pennsylvania; Professor of Virology at the Wistar Institute and Medical and Scientific Director of Pasteur-Merieux-Connaught (now Sanofi Pasteur). Dr. Plotkin developed the rubella vaccine now in standard use throughout the world, and has worked extensively on the development and application of other vaccines including polio, rabies, varicella, rotavirus and cytomegalovirus.
Philip K. Russell, M.D., U.S. Army Major General (retired), is Professor Emeritus of the Johns Hopkins School of Hygiene and Public Health. Prior to joining the University, Dr. Russell served as head of the U.S. Army Medical Research and Development Command. He has been directly involved in the development of several vaccines including adenovirus, meningitis, hepatitis A, dengue, and Japanese encephalitis. Dr. Russell has recently served as a Special Adviser in the Office of Public Health Emergency Preparedness, in the Office of the Secretary, Department of Health and Human Services where he directed the development and acquisition of biodefense vaccines and antitoxins for the Strategic National Stockpile under Project BioShield.
Sir John Skehel, Ph.D., FRS, FMedSci, is a world-renowned expert on the influenza virus. He led the team that first deciphered the structural and molecular interactions of the flu virus surface proteins and its host cell receptors. Sir John served as the Director of the Medical Research Council's National Institute for Medical Research in London from 1987-2006. He is Honorary Professor at the University College London and Vice President of The Academy of Medical Sciences in the U.K.
Jean-Louis Virelizier, M.D., is an internationally recognized immunologist with particular expertise in immunological memory and vaccine-induced immunity. He is Honorary Professor of the Institut Pasteur in Paris and is active in Pasteur international affairs and teaching. Dr. Virelizier's distinguished career at the Institut Pasteur included Head of the Molecular Medicine department and Head of the Immunity to Viruses research unit.
Vidadi Yusibov, Ph.D., is Executive Director of the Fraunhofer USA Center for Molecular Biotechnology (CMB). He is an expert in plant molecular biology and is the inventor of the technology for plant-made biopharmaceuticals licensed by InB:Biotechnologies. Prior to joining Fraunhofer USA CMB in 2001 as Scientific Director, Dr. Yusibov was an Assistant Professor of Microbiology and Immunology at Thomas Jefferson University. Dr. Yusibov has been a Director of Integrated BioPharma, Inc. since February 2006.
About Integrated BioPharma, Inc. (INBP)
Integrated BioPharma is a unique grouping of companies presently serving the varied needs of the health care industry. Through its nutraceutical business, the Company creates, develops, manufactures and markets products worldwide. The Company's biotechnology business uses its patented plant-based technology to produce vaccines and therapeutic antibodies. Its pharmaceutical business operates a GMP facility for the production and sale of Paclitaxel and related drugs and provides technical services through its contract research organization. Further information is available at www.ibiopharma.com
Statements included in this release related to Integrated BioPharma, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such Statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential risk factors that could affect the company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.